Kremsner P G, Wildling E, Jenne L, Graninger W, Bienzle U
International Research Laboratory of the Albert-Schweitzer-Hospital, Lambarene, Gabon.
Am J Trop Med Hyg. 1994 Jun;50(6):790-5. doi: 10.4269/ajtmh.1994.50.790.
Multidrug resistance of Plasmodium falciparum is spreading throughout Africa. In Lambarene, Gabon where chloroquine-resistant malaria is prevalent, a randomized comparative trial with three regimens for treating P. falciparum malaria in adults was performed. One hundred two patients evaluated received either a new micronized formulation of halofantrine (8 mg/kg every 6 hr in three doses) (group H) or chloroquine (25 mg/kg for a 48-hr period) plus clindamycin (5 mg/kg every 12 hr in six doses) (group CC1), or chloroquine (as above) plus doxycycline (2 mg/kg every 12 hr in six doses) (group CD). All treatment regimens were well-tolerated. In group H, 100% of the patients were cured, and in group CC1, 97% of the patients were cured by day 28 of follow-up. In group CD, a significantly lower cure rate of 75% (P < 0.01) and a slower parasite clearance was observed, but only low grade (RI) resistance occurred.
恶性疟原虫的多重耐药性正在非洲各地蔓延。在加蓬的兰巴雷内，耐氯喹疟疾盛行，在此进行了一项针对成人恶性疟原虫疟疾三种治疗方案的随机对照试验。102名接受评估的患者分别接受了新的微粉化卤泛群制剂（每6小时8毫克/千克，分三次给药）（H组），或氯喹（48小时内25毫克/千克）加克林霉素（每12小时5毫克/千克，分六次给药）（CC1组），或氯喹（如上）加多西环素（每12小时2毫克/千克，分六次给药）（CD组）。所有治疗方案耐受性良好。在H组中，100%的患者治愈；在CC1组中，随访至第28天时97%的患者治愈。在CD组中，治愈率显著较低，为75%（P<0.01），且寄生虫清除较慢，但仅出现低级别（RI）耐药。
